Ardsley Advisory Partners’s Legend Biotech LEGN Stock Holding History

Ardsley Advisory Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-140,000	Closed	-$7.85M	–	162
2024 Q1	$7.85M	Buy	140,000 +55,000	+65%	+$3.32M	1.13%	26
2023 Q4	$5.11M	Hold	85,000	–	–	0.79%	37
2023 Q3	$5.71M	Sell	85,000 -75,000	-47%	-$5.21M	1.27%	25
2023 Q2	$11M	Sell	160,000 -20,000	-11%	-$1.31M	1.87%	11
2023 Q1	$8.68M	Buy	+180,000	New	+$8.8M	1.91%	15
2022 Q3	–	Sell	-81,000	Closed	-$4.46M	–	128
2022 Q2	$4.46M	Buy	+81,000	New	+$3.42M	0.73%	39

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ardsley Advisory Partners's LEGN Position: Q2 2024 in Review

Ardsley Advisory Partners sold out of Legend Biotech (LEGN) in Q2 2024, closing a stake of 140,000 shares — an estimated $7.85M sold.

Ardsley Advisory Partners first reported a position in LEGN in Q2 2022 and held it in 6 quarters. The position peaked at $11M in Q2 2023. 181 funds tracked by Wall St. Rank hold LEGN as of Q2 2024.

Ardsley Advisory Partners reported no remaining Legend Biotech position as of Q2 2024 after selling out during the quarter.
Ardsley Advisory Partners sold 140,000 Legend Biotech shares in Q2 2024, an estimated $7.85M.
Ardsley Advisory Partners first reported a position in Legend Biotech in Q2 2022 and held it in 6 quarters.
Ardsley Advisory Partners's Legend Biotech position peaked at $11M in Q2 2023.
181 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2024.

Based on Ardsley Advisory Partners's 13F filing for Q2 2024, filed 14 Aug 2024.